DeepMed Research

INSIGHTEC, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients

Conditions: Glioma, Malignant
Glioblastoma

Interventions: Device: Magnetic Resonance guided Focused ultrasound (MRgFUS)

First Posted Date: 2021-08-10

Last Posted Date: 2022-01-06

Lead Sponsor: InSightec

Target Recruit Count: 5

Registration Number: NCT04998864

Locations: 🇮🇹
Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy
🇪🇸
CINAC-Hospital HM Puerta del Sur, Móstoles, Madrid, Spain

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease

Recruiting

Conditions: Tremor Associated With Tremor Dominant Parkinson's Disease

Interventions: Device: Unilateral thalamotomy

First Posted Date: 2021-08-05

Last Posted Date: 2025-04-30

Lead Sponsor: InSightec

Target Recruit Count: 50

Registration Number: NCT04991831

Locations: 🇺🇸
Miami Neuroscience Institute Baptist Health, Miami, Florida, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States

and more 5 locations

A Clinical Trial for the Safety and Effect of MRGuided FUS Subthalamotomy for Medication Refractory Parkinson's Disease

Not Applicable

Completed

Conditions: Parkinson Disease

Interventions: Device: ExaBlate 4000

First Posted Date: 2021-02-09

Last Posted Date: 2024-03-06

Lead Sponsor: InSightec

Target Recruit Count: 10

Registration Number: NCT04744493

Locations: 🇯🇵
Osaka University Hospital, Suita, Osaka, Japan

Evaluation of the Safety and Effectiveness of Bilateral Exablate Ablation of the Pallidothalamic Tract (PTT) for the Treatment of the Motor Complications of Parkinson's Disease (PD)

Not Applicable

Active, not recruiting

Conditions: Parkinson Disease

Interventions: Device: Exablate 4000

First Posted Date: 2021-01-28

Last Posted Date: 2025-02-17

Lead Sponsor: InSightec

Target Recruit Count: 50

Registration Number: NCT04728295

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Stanford, Palo Alto, California, United States
🇪🇸
Neurology, Hospital Universitario HM Puerta del Sur (HM CINAC), Madrid, Spain

and more 6 locations

Safety and Effectiveness of Blood-Brain Barrier Disruption (BBBD) in Subjects With Suspected Infiltrating Glioma

Not Applicable

Withdrawn

Conditions: Glioma

Interventions: Device: Exablate BBBD

First Posted Date: 2020-12-16

Last Posted Date: 2025-05-02

Lead Sponsor: InSightec

Target Recruit Count: 120

Registration Number: NCT04667715

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study of MRgFUS Exablate Treatment Following the Neuropathic Pain

Not Applicable

Conditions: Neuropathic Pain

Interventions: Device: Exablate treatment

First Posted Date: 2020-12-02

Last Posted Date: 2020-12-02

Lead Sponsor: InSightec

Target Recruit Count: 30

Registration Number: NCT04649554

Locations: 🇮🇹
Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

Phase 1

Active, not recruiting

Conditions: Recurrent Glioblastoma

Interventions: Device: Exablate BBBD
Drug: Carboplatin

First Posted Date: 2020-06-19

Last Posted Date: 2024-03-13

Lead Sponsor: InSightec

Target Recruit Count: 13

Registration Number: NCT04440358

Locations: 🇰🇷
Yonsei University Medical Center, Seoul, Korea, Republic of
🇮🇹
Fondazione IRCCS Neurologico Carlo Besta, Milano, Italy
🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

Phase 1

Active, not recruiting

Conditions: Recurrent Glioblastoma

Interventions: Drug: Carboplatin
Device: Exablate BBBD

First Posted Date: 2020-06-04

Last Posted Date: 2024-03-05

Lead Sponsor: InSightec

Target Recruit Count: 30

Registration Number: NCT04417088

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States

and more 1 locations

Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease

Not Applicable

Conditions: Parkinson Disease

Interventions: Device: Exablate BBBD with Cerezyme

First Posted Date: 2020-05-01

Last Posted Date: 2022-08-02

Lead Sponsor: InSightec

Target Recruit Count: 4

Registration Number: NCT04370665

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Exablate for LIFU Neuromodulation in Patients with Opioid Use Disorder (OUD) And/or Other Substance Use Disorders (SUDs)

Not Applicable

Recruiting

Conditions: Opioid-use Disorder
Substance Use Disorders

Interventions: Device: Exablate Model 4000 Type 2.0/2.1

First Posted Date: 2019-12-13

Last Posted Date: 2025-01-21

Lead Sponsor: InSightec

Target Recruit Count: 29

Registration Number: NCT04197921

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States
🇺🇸
West Virginia University: Rockefeller Neuroscience Institute, Morgantown, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy